source
- Windward Bio targets $204M Nasdaq IPO to fund Chinese respiratory drug programWindward Bio, a biotech backed by Sanofi, announced plans to go public on Nasdaq with an offering of 10.3 million shares priced between $16 and $18 each. The company expects net proceeds of about $…
- Valneva's Shigella vaccine cuts infection rates in phase 2 trialValneva reported that its Shigella vaccine reduced the number of intestinal infections in a phase 2 controlled human infection model study conducted in the United States. The trial enrolled 120 he…